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When bacteria such as Staphylococcus aureus and Streptococcus pneumoniae are exposed to
lytic antibiotics such as penicillin and vancomycin, a self-induced killing process is
initiated in the organism. This killing occurs via both non-lytic and lytic processes. Recent
data suggest that the non-lytic killing system, which might affect the cytoplasmic
membrane, secondarily activates murein hydrolases that eventually lyse the cell. Dis-
turbances in this suicide pathway can lead to antibiotic tolerance, a process whereby the
antibiotic still exerts its bacteriostatic effects but the self-induced killing system is
impaired. In mutants obtained in vitro, signaling pathways have been affected that
show either increased or decreased antibiotic-induced killing. Among clinical isolates of
S. pneumoniae that are tolerant to penicillin and/or vancomycin, we do not yet know
whether these signaling pathways are affected. We could, however, demonstrate that the
activity of murein hydrolases is negatively controlled by the production of capsular
polysaccharides in one vancomycin-tolerant isolate. Hence, type and level of capsular
expressionmight constitute one factor that determines the degree of lysis, once the killing
signal has been elicited by the antibiotic.
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INTRODUCTION
Streptococcus pneumoniae is a major contributor to
community-acquired disease such as otitis media,
meningitis, septicemia and pneumonia in children
and in adults [1–3]. Despite the fact that pneumo-
cocci cause severe diseases, they are also found in
up to 50% of healthy children attending day-care
centers. Penicillin has been the drug of choice for
these common infections for decades, but because
of increasing antibiotic resistance, broad-spectrum
antibiotics are often needed. Up to 50% penicillin
resistance has been observed in many parts of
the world, as well as multiresistance (resistance
to more than two antibiotics) [4–7]. More knowl-
edge mechanisms of development of antibiotic
resistance will help us to win the battle against
these threatening bacteria.
Even though penicillin has been known as
an antibacterial agent for over 70 years, we still
do not fully understand how this antibiotic exerts
its killing activity. It was initially believed that the
lysis associated with penicillin action was caused
by an inhibition of peptidoglycan assembly, result-
ing in a weakened cell wall that eventually
exploded due to the rising internal osmotic pres-
sure [8]. It later became evident that bacterial lysis
was not a mechanical process but required the
action of bacterial lytic enzymes, murein hydro-
lases [9,10]. However, penicillin-induced killing
cannot solely be explained by self-induced lysis
caused by murein hydrolases, since bacterial
mutants deﬁcient in murein hydrolase activity can
still be killed by penicillin, even though the killing
processmight be slower [11].Models have recently
been proposed in which a non-lytic killing signal
initiates the death process, followed by activation
of lytic enzymes that lyse the organism [12].
Any process that interferes with penicillin-
induced killing will probably affect the rate at
which the organism is killed following drug treat-
ment. However, reduced killing will not necessa-
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rily affect the MIC value for the organism, since
inhibition of peptidoglycan assembly by penicillin
will prevent growth. Translated to a clinical situa-
tion, this decreased killing rate would potentially
result in an increased number of survivors once
the concentration of penicillin dropped below the
MIC value for the microbe. The term penicillin
tolerance describes bacterial strains for which
penicillin retains its bacteriostatic activity, since
the penicillin-binding target proteins are normally
not affected, but there is a decreased response to
the killing signal triggered by penicillin action.
Penicillins do not affect non-growing bacteria,
and deprivation of nutrients as well as a low pH
in the media creates tolerance, called phenotypic
tolerance [13]. Genotypic tolerance means that
mutations in speciﬁc genes create tolerance.
Penicillin tolerance in S. pneumoniae was ﬁrst
described in 1970 by Alexander Tomasz, who
observed a peculiar penicillin response of some
laboratory strains [10]. Ordinary pneumococcal
strains would lyse rapidly and lose viability when
exposed to penicillin above the MIC, whereas the
new strains identiﬁed did not lyse, and lost via-
bility at a lower rate [14–16].
Vancomycin is another lytic antibiotic inhibiting
peptidoglycan synthesis, but it does so at an earlier
step than penicillin. Tolerant strains have recently
been described, both as mutants of laboratory
strains and as naturally occurring clinical isolates
[16–19]. Even though these strains continue to show
susceptibility to vancomycin as measured by MIC,
these tolerant isolates are of concern, since vanco-
mycin represents a last resort in the case of serious
infections with multiresistant pneumococci [20].
Since penicillin- and vancomycin-tolerant bac-
teria show the same MIC as non-tolerant bacteria,
they are difﬁcult to identify [18]. It has therefore
been difﬁcult to assess the importance of tolerance
in clinical settings. Antibiotic-tolerant organisms
may be involved in therapeutic failure and may
also represent a platform for building up antibiotic
resistance [21]. Since antibiotic-tolerant pneumo-
cocci are, in general, less lytic, such bacteria might
alsocause infection thatgeneratesanaltered inﬂam-
matory response compared to fully lytic organisms.
HOW IS ANTIBIOTIC TOLERANCE
MEASURED AND DEFINED IN
STREPTOCOCCUS PNEUMONIAE?
A normally fully lytic culture of a non-tolerant
strain of S. pneumoniae is almost totally lysed after
4 h when benzylpenicillin at 10MIC is added to
logarithmically growing cells. Viable count mea-
surements after 4 h demonstrate that less than
about 0.1% of bacteria present at the time of anti-
biotic exposure survive after 4 h. A typical peni-
cillin-tolerant culture of S. pneumoniae is usually
not lysed or only partially lysed under the same
conditions, and about 1% of the bacteria initially
present remain viable [18]. For vancomycin, we
have suggested that pneumococci showing more
than 1% survival after 4 h of growth in the presence
of 10MIC should be considered tolerant. Should
treatment with penicillin or vancomycin be
extended beyond 4 h, an even lower fraction of
surviving bacteria would be found for both toler-
ant and non-tolerant bacteria. Antibiotic tolerance
has also been detected by measuring the ratio
between minimum bactericidal concentration
(MBC) and MIC. Strains showing a high MBC/
MIC ratio have been suggested to be antibiotic
tolerant, but this method suffers from difﬁculties
in reproducibility [22].
It should be noted that so far we have not come
across a clinical isolate of S. pneumoniae showing
100% survival, as measured by viable count, after
4 h of treatment with penicillin or vancomycin at
10MIC [18]. If such isolates were to develop in
clinical settings, as they can in the laboratory,
tolerance would rapidly become a highly signiﬁ-
cant clinical problem. The tolerant clinical isolates
that we have studied will eventually be killed after
long exposure to lytic antibiotics. Keeping the
antibiotic concentration well over the MIC for a
sufﬁciently long period is probably important to
eradicate tolerant bacteria.
HOW DO PENICILLIN AND
VANCOMYCIN KILL MICROBES?
Penicillin
The targets for b-lactams are the penicillin-binding
proteins (PBPs) that catalyze transpeptidation of
the stem peptides required for cross-linking the
peptidoglycan cell wall, as well as the DD-carbox-
ypeptidation step required to remove terminal D-
alanine from the stem peptides (Figure 1). Some of
the larger PBPs also have transglycosidase activity,
allowing for the covalent joining of the incoming
disaccharide–muramylpentapeptide with the pre-
existing glycan part of the wall. In the pneumo-
coccus, there are ﬁve high-molecular-weight pbp
genes in the recently completed genome of S.
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pneumoniae, pbp1a, pbp1b, pbp2a, pbp2b and pbp2x,
and at least one low-molecular-weight pbp gene,
pbp3 [23]. Inhibition of PBP2b has been proposed to
be crucial for the induction of lysis [24]. Third-
generation cephalosporins induce less lysis in
pneumococci, and one reason suggested is that
they do not interact with PBP2b [25].
Through horizontal gene transfer of pbp genes
and gene fragments from related oral streptococci,
penicillin-resistant strains have evolved in S. pneu-
moniae containing one or more low-afﬁnity var-
iants of PBP proteins [26–31]. These newly evolved
PBPs have altered kinetic properties with regard to
b-lactam antibiotics, usually visualized as reduced
afﬁnity for penicillin in PBP-binding assays. At the
same time, the low-afﬁnity PBP variants have to
maintain their normal catalytic ability with stem
peptides as substrates.
Thepneumococcusproducesbranchedstempep-
tides. The degree of such branching differs among
different strains. Branching requires the activity of
themurMNgenes. Itwasrecentlydemonstratedthat
a penicillin-resistant pneumococcal strain lost its
resistance phenotype if the murMN genes were
inactivated [32]. Branched stem peptides contain
shortAla–AlaorAla–Sersubstituentson theepsilon
amino group of the lysine residues [33–35]. During
cross-linking, the terminal alanine residue in the
branch is used in PBP-catalyzed transpeptidation
reactionswith the D-alanine in the fourthposition of
a neighboring stem peptide. One could therefore
envisage that penicillin-resistant PBPs might be
prevented from using all types of stem peptides as
substrates during normal peptidoglycan assembly.
Somehow, murMN mutants sensitized the pneu-
mococcus to the killing activity of penicillin [32].
It would be interesting to know if this sensitization
extends to other lytic antibiotics. The phenomenon
of increased susceptibility to penicillin-induced
killing may be the other side of the coin that deter-
mines decreased killing activity by penicillin.
Vancomycin
Vancomycin exerts its antibacterial activity by
binding to D-Ala– D-Ala termini of peptidoglycan
precursors, preventing these from being incorpo-
rated into the growing peptidoglycan cell wall.
Enterococci resistant to vancomycin carry the vanA
or vanB gene cluster, which allows some of the
peptidoglycan precursors to terminate with D-
Ala– D-Lac, which precludes binding to vancomy-
cin [36,37]. Recently, a vancomycin-resistant clin-
ical isolate of S. aureus was observed [38]. These
strains produced a dramatically thickened cell
wall with a lower degree of cross-linking. It was
suggested that this altered cell wall acts as an
afﬁnity trap for vancomycin in the outer cell wall
layers, preventing its access to peptidoglycan pre-
cursors [39]. However, so far, vancomycin resis-
tance has not been reported in pneumococci.
THE TARGET, PEPTIDOGLYCAN
The bacterial peptidoglycan (murein) is intimately
linked to growth, morphogenesis and division of
bacterial cells. Thus, an organism such as Escher-
ichia coli or S. pneumoniae has a deﬁned growth
cycle, involving elongation, while maintaining the
diameter of the cell, and eventually the formation
of a cross-wall, in the middle of which cell division
will complete the formation of two daughter cells.
Peptidoglycan synthesis is probably carried out in
a process where the pre-existing peptidoglycan
can operate as a template. A model has been
proposed for the way E. coli (a Gram-negative
organism which, unlike Gram-positive bacteria,
has a very thin peptidoglycan wall) can control
its morphogenesis [40]. According to the so-called
three-for-one model, three murein strands are
synthesized underneath a pre-existing docking
strand [41]. In a second step, the docking strand
is degraded by speciﬁc murein hydrolases. The
newly formed triplet strands are next moved into
the growing peptidoglycan structure at the
expense of one strand. In this model, murein
hydrolysis is an integral and essential component
for both elongation and cross-wall formation. The
most signiﬁcant phenotype associated with bacter-
Figure 1 Schematic representation of the pneumococcal
peptidoglycan. It indicates the action of penicillin (Pc) and
vancomycin (Van) on penicillin-binding proteins (PBP) and
D-Ala– D-Ala termini, respectively. The site of action for the
major autolysin (LytA) in pneumococci is indicated. The
variable presence of branched stem peptides is indicated
on the left.
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ial mutants deﬁcient inmurein hydrolase activity is
the formationof long chainsof cells kept together by
a cross-wall that has not split, suggesting a critical
role for murein hydrolases in cell separation.
MUREIN HYDROLASES IN
STREPTOCOCCUS PNEUMONIAE
AND THEIR ROLE IN ANTIBIOTIC
TOLERANCE
Studies on antibiotic tolerance have primarily been
performed on E. coli, S. aureus and S. pneumoniae.
Penicillin-induced killing in these three groups of
organisms seems to partially involve activation of
murein hydrolases. Since murein hydrolases are
potentially suicide enzymes, they have to be tightly
controlled during normal growth conditions. This
control can be exerted at the level of transcription,
post-transcriptionally, at the level of secretion, by
substrate modiﬁcation, or by activation or inter-
ference via other cell wall components.
In the pneumococcus there are three known
murein hydrolases, LytA, LytB, and LytC, but
there are probably additional ones yet to be dis-
covered. LytA is an N-acetylmuramyl-L-alanine
amidase that cleaves the stem peptide off the
glycan backbone [42,43]. LytA belongs to a large
class of so-called choline-binding proteins, which
are anchored to the wall via choline residues on
lipoteichoic and teichoic acids. The two murein
hydrolases, LytB and LytC, are also choline-bind-
ing proteins that are tightly bound to the cell
envelope. While LytC has been characterized as
a lysozyme and behaves as an autolysin at 30 8C
[44], LytB appears to be the main hydrolase
responsible for cell separation, since inactivation
of lytB leads to the formation of extremely long
chains [45]. Pneumococci may also harbor phages
that can express an amidase similar to LytA in
order to lyse the bacterium, allowing for the
release of the phage. One such phage-encoded
amidase, PAL, was recently shown to be effective
in removing pneumococci from the nasopharynx
in a murine carriage model [46].
LytA is the only pneumococcal murein hydro-
lase that has ﬁrmly been associated with antibiotic
tolerance. LytA appears to be constitutively
expressed, yet this enzyme has to be controlled
to prevent spontaneous autolysis. S. pneumoniae
typically undergoes spontaneous lysis upon reach-
ing the stationary phase. An overnight culture of
strain R6 is almost totally lysed, and less than 0.1%
of the bacteria in the culture survive the night. In a
lytA mutant derivative of R6, there is virtually no
spontaneous stationary-phase lysis, andmore than
1% of the bacteria in the culture remain viable
[15,18]. These simple observations suggest that,
during logarithmic growth, LytA is somehow pre-
vented from lysing the bacterium. This negative
control is relieved when the organism reaches the
stationary phase, resulting in spontaneous lysis. It
is not clear why pneumococci voluntarily commit
suicide in aging cultures. One hypothesis is that
this initial overnight lysis of the culture results in a
small number of survivors, which can then go on
and survive for a considerable amount of time,
potentially using their lysed relatives as nutri-
tional substrates. Recent data from our laboratory
have shown that in a fully lytic culture of R6 a few
viable survivors remain for more than 20 days. In
the lytA mutant derivative of R6, however, there
are no long-term survivors, even though there is
no lysis of the culture. Hence, spontaneous lysis
may be of selective advantage for the pneumococ-
cus under prolonged periods of nutritional depri-
vation (to be published).
A lytA mutant of R6 had not only lost its spon-
taneous autolysis but was also non-lytic after treat-
ment with benzylpenicillin as well as vancomycin.
LytA is, as already mentioned, produced through-
out the pneumococcal growth cycle, and there is
no induction of the gene when lytic antibiotics are
added. Consequently, lytic antibiotics must trigger
a response in the pneumococcus, resulting either
in the enzymatic activation of LytA or in making
the peptidoglycan substrate accessible to the
enzyme. In either case, lytic antibiotics would
result in self-inﬂicted death through lysis. Even
though a lytAmutant is not lysed by penicillin and
vancomycin, these agents remain able to kill the
organism; however, the killing process is slower.
In a tolerance assay, a lytAmutant of R6 is tolerant
to both penicillin (more than about 1% surviving
bacteria) and to vancomycin (more than about 1%
surviving bacteria). However, since both penicillin
and vancomycin result in signiﬁcant killing with-
out any measurable lysis, these antibiotics must be
able to trigger a death process that occurs inde-
pendently of bacterial lysis.
BACTERIOPHAGE-INDUCED LYSIS
MAY TEACH US ABOUT
ANTIBIOTIC- INDUCED LYSIS
Even though we have no knowledge about the
killing mechanism in pneumococci that occurs in
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the absence of bacterial lysis, studies in other
organisms, particularly E. coli, have revealed a
number of events that can result in programmed
death. Bacteriophages must be able to kill and lyse
their bacterial host in order to be liberated. For
most bacteriophages, lysis of the host requires at
least two proteins: a murein hydrolase and a holin.
Holins are integral membrane proteins that control
the access of phage-encoded murein hydrolases to
the cell wall [47]. They do so by the sudden forma-
tion of a hole in the cytoplasmic membrane, at a
precisely deﬁned time. This causes a disruption of
membrane function that is lethal in itself, but also
leads to lysis by allowing murein hydrolase to
attack the peptidoglycan [48]. Holins may be con-
trolled by antiholins, which prevent hole forma-
tion [49].
If penicillin and vancomycin could somehow
trigger formation of holin pores in the membrane,
we would have a hypothetical mechanism for the
initial effector step inpenicillin-inducedkilling [12].
PROGRAMMED CELL DEATH UPON
PLASMID LOSS
Through a mechanism known as post-segrega-
tional killing, several plasmids in E. coli, such as
the antibiotic resistance plasmid R1, ensure their
maintenance by carrying genes that kill those cells
that have lost the plasmid. The plasmid encodes
the Hok toxin on an unusually stable mRNA. This
mRNA is prevented from being translated by base
pairing with the sok mRNA, which has a much
shorter half-life. If a bacterium loses its plasmid,
sok mRNA will be degraded before the mRNA of
hok. hok mRNA free of its antisense inhibitor will
now be translated into the toxin that kills the
microbe [50]. Thus, programmed cell death in
bacteria might operate via a killer system con-
trolled by an antikiller at the level of RNA–RNA
pairing and degradation.
BACTERIAL CELL DIVISION SITES
ARE PARTICULARLY SENSITIVE TO
PENICILLIN-INDUCED KILLING
AND LYSIS
One basic necessity for a bacterium is to have a
robust and reliable system that tells it when to
divide and where to locate the division site. This
process has to ensure that each daughter cell gets a
complete chromosome. The FtZ protein initiates
cell division in all known bacteria. FtsZ forms an
annular structure at the forming division site [51].
In an ftsZmutant that assembles FtsZ into a spiral,
the resulting constriction also becomes spiral-
shaped [52]. If Ftz rings are assembled, bymistake,
close to one of the two bacterial poles, the organ-
ism will divide, giving rise to one non-viable
minicell lacking DNA, and another larger cell
containing all the genetic information. To ensure
that FtsZ only forms a ring in the middle of cells
that have grown to a size twice that of newborn
bacteria, the bacterium produces proteins that
inhibit FtsZ assembly [53]. The FtsZ inhibitor
MinC, under the control of MinD and MinE, is
unusual in that it can oscillate from one pole to
another, resulting in the lowest concentration
being halfway between the poles [54]. At a certain
length of the microbe, MinCD will reach a lower
threshold concentration, resulting in FtsZ assem-
bly and subsequent cell division at the middle of
the cell [55]. A disturbance of this elegant system
will result in defective cell divisionmachinery. The
bacterial peptidoglycan, the target for penicillin
and vancomycin action, will change growth direc-
tion when a division site has been deﬁned by the
assembly of FtsZ. At least in E. coli, a speciﬁc trans-
peptidase, FtsI (formerly PBP3), is involved in
forming the cross-wall. The correct interplay
between FtsI, other cell division proteins and FtsZ
is crucial for cell division [56,57]. Recent results in
studies with E. coli strongly support the idea that
b-lactam-induced lysis occurs preferentially at
division sites because of the activation of zonal
murein synthesis at the initiation of septation [58].
Also, in pneumococci one or more of the PBPs
are likely to be involved primarily in cross-wall
formation. It is also likely that the division site is
particularly sensitive to penicillin-induced killing
and lysis.
TOWARDS UNDERSTANDING THE
SIGNALING PATHWAY LEADING TO
ANTIBIOTIC- INDUCED KILLING
(FIGURE 2)
Streptococcus pneumoniae
A series of penicillin- and/or vancomycin-tolerant
mutants was recently identiﬁed and characterized
in the laboratory strain R6 by Tuomanen’s group
(Table 1). These mutants still produced normal
amounts of LytA, but were neither lysed nor killed
by lytic antibiotics, suggesting that they had
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deﬁciencies in both the lytic and the non-lytic
death processes. A two-component system,
VncS/VncR, was identiﬁed in this search, where
inactivation of the membrane-bound histidine
kinase sensor VncS resulted in complete tolerance,
whereas inactivation of the corresponding VncR
response regulator had no measurable phenotype
[17]. The VncS sensor was therefore suggested to
be part of a signal transduction system leading to
antibiotic-induced death. So far there has been no
report of the target genes under the control of this
two-component system.
If pneumococcal VncSR is required to trigger
endogenous suicide, a major question is how lytic
antibiotics trigger this system. Gram-positive bac-
teria are well known to use secreted peptides in
different signaling systems. Close to the vncS gene
there is a short open reading frame that encodes a
27 amino acid peptide, Pep27, that has been pro-
posed to initiate the cell death program by inter-
acting with VncS. These data suggest a novel
model for the control of bacterial cell death which
involves sensing of a secreted peptide [59]. While
this model helps to explain why spontaneous lysis
is initiated only in dense cultures when Pep27 has
accumulated in the medium, it does not easily
explain the lysis that is triggered at a very low
density when lytic antibiotics are added to the
culture. It is important to know if lytic antibiotics
result in increased secretion of Pep27. An ABC
transporter, Vex, is encoded by genes close to
the open reading frame for Pep27. Inactivation of
this transporter has also been shown to result in
antibiotic tolerance [59]. The possibility that Vex
actually secretes Pep27 has been discussed. Pep27
has not yet been puriﬁed from the culture super-
natant and shown to trigger antibiotic-induced
death. The open reading frame encoding Pep27
is unusual, in that there is no propart. Other very
small biologically active peptides are usually
translated with a propart that is subsequently
Figure 2 A hypothetical model for b-lactam induced kill-
ing in Gram-positive bacteria. The experimental data come
from both Streptococcus pneumoniae and Staphylococcus
aureus. The b-lactam is depicted interacting with its
penicillin-binding protein (PBP) target. Inhibition of
peptidoglycan assembly triggers a signal that could result
in the secretion of a death peptide (Pep27), by an increased
release of soluble muropeptides from the pre-existing wall,
orby someunknownmechanism.The signal is recognizedby
a membrane-bound histidine kinase (HK) that can phos-
phorylate its cognate response regulator (RR). This event
will, by an unknown mechanism, activate a non-lytic killing
function that, as shown in the figure, could be carried out by
the formation of holin pores. The commitment to non-lytic
death will secondarily activate suicide murein hydrolases,
which will lyse the bacteria. The mechanism for this
activation is not known, but could involve holin pores, as in
bacteriophage-mediated lysis. Themajor autolysin activated
inS. pneumoniaeduringantibiotic-induced lysis isLytA.LytA
activity is affected by its interaction with choline residues on
lipoteichoic acids (LTA), andalso by the expression of certain
types of capsular polysaccharides.
Table 1 Suggested structures involved in penicillin tolerance in Streptococcus pneumoniae
Gene/structures Function Reference
PBP2b Tolerance via missense mutations [24]
murMN Increased penicillin-induced killing in KO [32]
vncS Penicillin and vancomycin tolerant in KO [17]
pep27 Induced autolytic activity [59]
Psa ABC transporter [67]a
ZmpB Zinc metalloprotease [68]a
ClpC Heat-shock protein [69]
CPS Capsular polysaccharide, inhibits lysis Henriques Normark et al. (unpublished)
LytA Major autolysin, amidase [70]
LytB Murein hydrolase, responsible for cell separation [45]
LytC Lysozyme [44]
aConflicting observations: [71] and [72].
KO, knockout mutants.
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cleaved off by a proteolytic event, releasing the
mature active peptide.
Staphylococcus aureus
A two-component system, LytSR, has recently
been identiﬁed in S. aureus that affects murein
hydrolase activity [60,61]. This system regulates
two potential membrane-associated proteins,
LrgA and LrgB. Inactivation of lrgAB resulted in
increased penicillin-induced killing that seemed to
occur in the absence of an increased degree of lysis
[61]. Hence, LrgAB expression acts to prevent
penicillin-induced killing. In a model recently
proposed by Bayles [12], LytSR in S. aureus posi-
tively controls the expression of LrgAB. LrgAB are
believed to act as antiholins for a bacterially en-
coded holin that is yet to be discovered [12]. If
muropeptides, released as a consequence of peni-
cillin action, are sensed by LytSR, a regulatory
route will be created whereby the bacterium
attempts to counteract the lethal signal created
by penicillin by overproducing antiholin. Clearly,
this attractive model requires the putative holin to
be identiﬁed. Also, we need to understand how
penicillin would stimulate pore formation by the
holin. In this model, holin pores in the cytoplasmic
membrane would be enough to kill the organism.
However, if the system operates as has been shown
for lytic bacteriophages, holin pores would also
result in the activation of lytic murein hydrolases.
TOLERANCE TO PENICILLIN AND
VANCOMYCIN AMONG CLINICAL
ISOLATES OF STREPTOCOCCUS
PNEUMONIAE
Penicillin
Among clinical isolates of pneumococci, different
studies have shown that 8–30% have reduced lysis
by benzylpenicillin and exhibit a tolerance pheno-
type to this antibiotic [15,18,62]. In all studied
cases, these isolates express normal levels of LytA
amidase, but it is not known if production of other
murein hydrolases is also normal.
Since most, if not all, penicillin-tolerant isolates
show reduced lysis, it has been suggested that this
non-lytic behavior might affect the degree of
inﬂammation that results from a pneumococcal
infection. Inﬂammatory responses are evoked by
conserved pattern molecules, such as peptidogly-
can fragments, lipoteichoic acids, lipoproteins, N-
formylated chemotactic peptides or CpG DNA,
which are probably released in larger quantities
from highly lytic organisms. Activation of inﬂam-
matory processes can be beneﬁcial (increased
clearing) as well as harmful (increased pathophy-
siology) to the host. Differences in lytic behavior
among clinical isolates of pneumococci may there-
fore have different consequences for the host,
depending on whether infection is local or disse-
minated and whether the organism has passed the
blood–brain barrier or not.
Vancomycin
We and others have recently reported on vanco-
mycin-tolerant pneumococci among clinical iso-
lates [18,19]. In our study of 116 isolates, three
were deﬁned as vancomycin tolerant [18]. They
were all of serotype 9V and clonally related, and
they also exhibited reduced susceptibility to peni-
cillin. Only one of these isolates was found to be
penicillin tolerant.The three isolatesgrewnormally,
showed no division abnormalities, and were lysed
by deoxycholate, suggesting normal production of
autolysin. We have subsequently shown, both by
Western blots using a LytA-speciﬁc antiserum and
by Northern blot hybridization, that the LytA
amidase is normally expressed in tolerant isolates.
One working hypothesis was that these vancomy-
cin-tolerant isolates carried mutations in VncS
that could affect antibiotic-induced signaling.
Even though alterations were found in the C-
terminal region of VncS, relative to a non-tolerant
isolate, we do not know if these differences have
any effects on VncS operating as a sensor.
Most basic studies on antibiotic tolerance in
Streptococcus pneumoniae have been carried out
on the non-encapsulated laboratory strain R6. By
contrast, virtually all clinical isolates exhibiting a
reduced lytic response to penicillin and/or van-
comycin are capsulated. Moreover, antibiotic tol-
erance seemed to be more common among certain
serotypes than others. A spontaneous mutant has
been recovered from one of our vancomycin-tol-
erant 9V isolates that had lost its ability to form a
9V capsule. Interestingly, this non-encapsulated
mutant was extensively lysed after both penicillin
and vancomycin treatment and was no longer
antibiotic tolerant (unpublished observations).
These preliminary data suggest that cell wall struc-
tures, such as capsular polysaccharides, may act to
prevent access of murein hydrolases to their pep-
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tidoglycan target. Since the cross-wall during cell
division might be expected to contain less capsule-
associated polysaccharide, compared to the per-
ipheral wall, murein hydrolases might be relieved
from capsular inhibition during the normal cell
division process.
Weiser et al. have identiﬁed a phase variation
system in pneumococci that might have a bearing
on our ﬁndings. So-called opaque colony variants
produced more capsular polysaccharides and
were less lytic compared to transparent-phase
variants. Interestingly, transparent variants were
associated with the carrier state in the nasophar-
ynx, whereas the opaque, less lytic variants were
preferentially found in the bloodstream [63].
CLINICAL RELEVANCE OF
ANTIBIOTIC TOLERANCE
Animal experiments
Studies on experimental endocarditis in rabbits by
Brennan and Durack showed that, of 36 rabbits
infected with tolerant Streptococcus sanguis II, none
was cured by treatment with penicillin for 5 days,
as compared to 23 rabbits infected with a non-
tolerant strain, of which 10 were cured [64]. Also,
in an experimental rabbit meningitis model, a
vancomycin-tolerant vncS mutant was more difﬁ-
cult to eradicate with vancomycin treatment than
its non-tolerant isogenic pair, indicating therapeu-
tic failure for the tolerant strain [17].
Clinical setting
Infections in humans with apparent treatment fail-
ures, caused by antibiotic-tolerant bacteria, have
been reported, suggesting a clinical signiﬁcance
for antibiotic tolerance [15,16,19]. It remains to be
determined, though, whether this phenomenon is
really of great importance in the clinical setting.
Recently,McCullersetal.reportedonavancomycin-
tolerantpneumococcal strain isolated from thecere-
brospinal ﬂuid of a child with meningitis. Despite
treatment with vancomycin and a third-generation
cephalosporin, the child developed recrudescent
meningitis after cessation of therapy [19]. Perhaps
antibiotic tolerance affects the development of
relapsing infections, especially in locations such
as the meninges, which antibiotics have difﬁculty
in penetrating and where the defense is poor.
Clinical failures have been reported in severe
invasive infections caused by group C and G strep-
tococci, and it has been suggested that one reason
might be antibiotic tolerance [65]. In 1980, Portnoy
et al. reported a bacterial endocarditis caused by a
penicillin-tolerant group C streptococcus, and re-
centlyvancomycin tolerancewasobserved ingroup
G streptococci causing invasive disease [65,66].
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